ADL Amdl,

TUSTIN, Calif., Oct. 24 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products, announced today that its JPI's subsidiary JJB has launched a new anti-aging and skin care injectable product under the brand name "Goodnak". This initial product is the first in a new line of anti-aging & skin care products currently under development by JJB. Goodnak is a high quality injectable anti-aging & skin care product that contains an amalgam of various therapeutic elements including human placental histosolution ("HPH"). JPI has begun selling Goodnak, in August, through wholesale distribution channels that service high-end beauty salon and plastic surgery hospitals and or medical cosmetology institutions. Goodnak product information is available on Jade Pharma's product specific website: http://www.jade-amdl.com/. JJB is highlighting its Goodnak product as a supporting sponsor of the Asia-Pacific Beauty & Cosmetics Convention being held in Harbin China from October 26th thru 28th. In concert with this new product launch, JJB has signed two new Northern Region exclusive, one-year renewable Distribution and Agency Agreements with Shenyang Beauty Bio-Chemistry Co., Ltd. ("SBB") and Harbin Beautiful Life Cosmetic Co., Ltd. ("HBL"). These agreements cover the key cities in both Liaoning and Heilongjiang Provinces that have a combined population of approximately 21.6 million people. These two separate agreements in combination require these new regional distributors to purchase a minimum of US$3,355,525 of JJB's new Goodnak product during the one-year period of the contracts and minimum initial orders of US$2,716,377. Frank Zheng, managing director of JPI, said this new product launch and initial distribution agreement puts the Company on the path to building sales of Goodnak by as much as $24 million over the next 12 months. Gary Dreher, CEO of AMDL said, we expect to further update the market on our expansion plans in the coming weeks. About JPI: Jade Pharmaceutical through its subsidiaries JJB & YYB has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards. About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com/. Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 VoiceMail: 714.505.4460 DATASOURCE: AMDL, Inc. CONTACT: Paul Knopick, Investor Relations, +1-949-707-5365, voice mail, +1-714-505-4460, for AMDL Web site: http://www.jade-amdl.com/ http://www.amdl.com/

Copyright